Skip to NavigationSkip to content

pharmaceutical

EMA approves Cimzia for use in treating plaque psoriasis

The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia (certolizumab pegol), to include a new indication in adult patients with moderate-to-severe plaque psoriasis.

The approval of the monoclonal antibody signals the multinational company’s entry into immune-dermatology. With an estimated 3% of the population or approximately 125 million people suffering from psoriasis across the globe, the disease area is one in which significant unmet need exists.

PTC Therapeutics’ results in SMA has Biogen nervous

IMAGE: PTC Therapeutics

Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that treatment is pretty central to the biotech’s portfolio, bringing in $364 million in revenue in the first quarter.

So, news that a competitor had posted strong results at Phase 1, with a more convenient method of delivery came as a blow to the company – enough to send shares down over 5%.

Roche buys out rest of Foundation Medicine for $2.4bn

Roche has clearly seen significant potential in Foundation Medicine’s work in genomics to pay $2.4 billion to take complete ownership of the company.

The big pharma company had already owned 58% of shares in Foundation Medicine, but decided to buy out the remaining shares to take the complete valuation of the company to $5.3 billion.

Foundation Medicine was founded in 2010 and is based just outside of Boston. It specialised in developing diagnostic tools to allow for targeted therapies to be chosen for patients.

Theranos founder charged with fraud

IMAGE: Glenn Fawcett

Going from the youngest female self-made billionaire in the world to being charged with engaging in schemes to defraud investors is a pretty spectacular fall from grace but that’s the fate of Elizabeth Holmes.

Once feted as the second-coming of Steve Jobs, Holmes had surged to fame as her company, Theranos, claimed to have developed a device that could analyse for a broad spectrum of diseases through just a pinprick of blood.

Maintaining control: The rising challenges of clinical data management

Published on 18/06/18 at 11:18am

From breach scandals to GDPR, data is becoming a more prominent part of our everyday lives. This holds great potential in the clinical space, but challenges are mounting rapidly, as Matt Fellows discovers.

HPV vaccine slashes rate of infection by 86% in UK

Since the introduction of the vaccination against the Human Papilloma Virus in 2008, there has been an 86% drop in the incidence of infection in women aged 16 to 21.

Recurrent HPV infections are the main cause of the majority of cases of cervical cancer and the introduction of vaccination for girls aged between 12 and 13 was brought in to protect women from facing the prospect of developing the cancer.

£20bn promised to NHS but questions over where money will come from

Image: Arno Mikkor

Theresa May finally attempted to tackle the elephant in the room for the UK government, well, the one other than progression of Brexit discussions, by pledging that the NHS would receive a funding boost of £20 billion per year.

The amount promised by May amounts to an increase in spending of 3.4% on the NHS annually, after a period under the coalition government where funding was limited to 1.1% increases and then rises averaging 2.3% under the Conservative government.

Top Ten most popular articles on Pharmafile.com this week

Another busy in week in pharma has seen a number of companies release promising data on their drugs, Roche's study highlighting the benefit of Ocrevus to MS patients. While in other news, J&J is looking to rid itself of excess weight and Mylan get hit by an FDA sucker punch.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Danger of Sanofi’s dengue vaccine confirmed in new study

New Jersey attempts to lure Teva HQ with tax incentives

Teva has been doing some major global restructuring since Kare Schultz came to the helm of the embattled, Israeli drugmaker. So deep were the cuts in Israel that a general strike briefly shut down most of the country, including its airport and banking services, in December 2017.

Undeterred, Shultz has pushed ahead and expanded those cuts to the North American market, shedding 200 workers from its North American headquarters in Pennsylvania at the beginning of the year.

Gene therapy offers hope for those with paralysis

Researchers at King’s College London (KCL) have made significant progress to being able to offer a treatment to those with paralysis due to spinal injuries.

The treatment is still in the early stages of testing, after the gene therapy was administered to rats, but offered significant hope as it saw the subjects able to use their front paws again.

The gene therapy works by delivering a gene that promotes the production of an enzyme called chondroitinase directly into the spine.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches